Nektar Therapeutics buy melinda
Summary
This prediction ended on 29.12.17 with a price of €54.57. The prediction had a final performance of 21.22%. melinda has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Nektar Therapeutics | -4.788% | -4.788% | 134.268% | -89.378% |
| iShares Core DAX® | -0.268% | 5.471% | 14.271% | 19.027% |
| iShares Nasdaq 100 | 1.854% | 7.851% | 35.426% | 58.415% |
| iShares Nikkei 225® | 0.284% | 1.729% | 9.943% | 7.045% |
| iShares S&P 500 | 1.178% | 5.269% | 27.989% | 49.400% |
Comments by melinda for this prediction
In the thread Nektar Therapeutics diskutieren
Biotechnologie und Medizintechnik SecteurRecherche Agenda 28/02 Ergebnisse Veröffentlichung
Nektar Therapeutics ist eine klinische Phase - biopharmazeutisches Unternehmen, die sich in Entwicklung Kandidaten qui Droge bitte icts Das PEGylierung und Polymer - Konjugat - Technologie platforms.Its Produkte enthalten Wirkstoffkandidaten von therapeutischen Bereichen verwendet werden , einschließlich Onkologie, Schmerz, Antiinfektiva, Anti-überhöht
Stopped prediction by melinda for Nektar Therapeutics
Nektar Therapeutics
16.05.18
08.11.18
08.11.18
Nektar Therapeutics
21.11.17
29.12.17
29.12.17
Nektar Therapeutics
20.06.13
20.12.13
20.12.13